Enlivex Therapeutics Ltd ENLV:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/10/24 EDT
1.50quote price arrow down-0.02 (-1.32%)
Volume
38,760
52 week range
1.15 - 4.59
Loading...
  • Open1.51
  • Day High1.53
  • Day Low1.43
  • Prev Close1.52
  • 52 Week High4.59
  • 52 Week High Date04/03/24
  • 52 Week Low1.15
  • 52 Week Low Date04/15/24

Key Stats

  • Market Cap28.218M
  • Shares Out18.81M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta1.29
  • YTD % Change-44.44

KEY STATS

  • Open1.51
  • Day High1.53
  • Day Low1.43
  • Prev Close1.52
  • 52 Week High4.59
  • 52 Week High Date04/03/24
  • 52 Week Low1.15
  • 52 Week Low Date04/15/24
  • Market Cap28.218M
  • Shares Out18.81M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta1.29
  • YTD % Change-44.44

RATIOS/PROFITABILITY

  • EPS (TTM)-1.56
  • P/E (TTM)-0.96
  • Fwd P/E (NTM)-1.74
  • EBITDA (TTM)-24.316M
  • ROE (TTM)-66.88%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date09/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Enlivex Therapeutics Ltd

 

Profile

MORE
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute...
Shai Novik
Executive Chairman of the Board
Oren Hershkovitz Ph.D.
Chief Executive Officer
Shachar Shlosberger CPA
Chief Financial Officer
Address
14 Einstein St.
Ness-ziona
7403618
Israel

Top Peers

SYMBOLLASTCHG%CHG
CNTX
Context Therapeutics Inc
1.87+0.04+2.19%
RNXT
RenovoRx Inc
1.45+0.10+7.81%
VIRX
Viracta Therapeutics Inc
0.76-0.065-7.8788%
NGNE
Neurogene Inc
32.50-0.71-2.14%
ACHL
Achilles Therapeutics PLC
0.935+0.0164+1.7853%